A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema

2023-503683-16-00 Protocol Breye-C22-1005 Human pharmacology (Phase I) - Other Ended

Start 16 Oct 2023 · End 29 May 2025 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol Breye-C22-1005

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 4

Diabetic macular edema

Key facts

Sponsor
Breye Therapeutics ApS
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Eye Diseases [C11]
Trial duration
16 Oct 2023 → 29 May 2025
Decision date (initial)
2023-08-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Diabetic macular edema

VersionLevelCodeTermSystem organ class
20.1 LLT 10057934 Diabetic macular edema 10015919

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Breye Therapeutics ApS

Sponsor organisation
Breye Therapeutics ApS
Address
Ved Hegnet 2
City
Rungsted Kyst
Postcode
2960
Country
Denmark

Scientific contact point

Organisation
Breye Therapeutics ApS
Contact name
Ulrik Mouritzen

Public contact point

Organisation
Breye Therapeutics ApS
Contact name
Ulrik Mouritzen

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 3 4
Rest of world
United States, United Kingdom
21

Investigational sites

Germany

4 sites · Ended
Universitaetsklinikum Bonn AöR
Augenklinik, Venusberg-Campus 1, Venusberg, Bonn
Universitaetsklinikum Tuebingen AöR
Augenklinik, Elfriede-Aulhorn-Strasse 7, Nordstadt, Tuebingen
Charite Universitaetsmedizin Berlin KöR
Augenklinik, Hindenburgdamm 30, Lichterfelde, Berlin
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Augenklinik, Langenbeckstrasse 1, Oberstadt, Mainz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-10-16 2025-05-28 2024-03-20 2025-01-27

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-06-07 Germany Acceptable
2023-08-03
2023-08-10
2 SUBSTANTIAL MODIFICATION SM-1 2023-09-18 Germany Acceptable
2023-10-12
2023-10-20
3 SUBSTANTIAL MODIFICATION SM-2 2023-11-10 Germany Acceptable 2023-12-15
4 SUBSTANTIAL MODIFICATION SM-3 2024-02-21 Germany Acceptable
2024-03-19
2024-03-21
5 SUBSTANTIAL MODIFICATION SM-4 2024-05-03 Germany Acceptable
2024-05-27
2024-06-05
6 SUBSTANTIAL MODIFICATION SM-5 2024-10-30 Germany Acceptable 2024-11-13
7 SUBSTANTIAL MODIFICATION SM-6 2024-12-11 Germany Acceptable
2025-01-21
2025-01-21